HomeCompareBAX vs HUN

BAX vs HUN: Dividend Comparison 2026

BAX yields 2.28% · HUN yields 5.37%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HUN wins by $75.6K in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
HUN
HUN
● Live price
5.37%
Share price
$12.57
Annual div
$0.68
5Y div CAGR
29.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$96.2K
Annual income
$25,291.10
Full HUN calculator →

Portfolio growth — BAX vs HUN

📍 HUN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXHUN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + HUN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
HUN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
HUN
Annual income on $10K today (after 15% tax)
$456.44/yr
After 10yr DRIP, annual income (after tax)
$21,497.43/yr
At 15% tax rate, HUN beats the other by $21,488.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + HUN for your $10,000?

BAX: 50%HUN: 50%
100% HUN50/50100% BAX
Portfolio after 10yr
$58.4K
Annual income
$12,650.68/yr
Blended yield
21.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BAX right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
HUN
Analyst Ratings
14
Buy
16
Hold
3
Sell
Consensus: Hold
Price Target
$11.80
-6.1% upside vs current
Range: $9.00 — $14.00
Altman Z
1.5
Piotroski
2/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
HUN buys
0
No recent congressional trades found for BAX or HUN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXHUN
Forward yield2.28%5.37%
Annual dividend / share$0.36$0.68
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%29.3%
Portfolio after 10y$20.6K$96.2K
Annual income after 10y$10.26$25,291.10
Total dividends collected$602.00$67.4K
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusHoldHold
Analyst price target$19.75$11.80

Year-by-year: BAX vs HUN ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrHUN PortfolioHUN Income/yrGap
1← crossover$10,866$166.33$11,394$694.33$528.00HUN
2$11,750$123.31$13,148$956.03$1.4KHUN
3$12,664$90.97$15,401$1,333.08$2.7KHUN
4$13,617$66.89$18,366$1,887.00$4.7KHUN
5$14,619$49.07$22,371$2,719.27$7.8KHUN
6$15,679$35.94$27,940$4,002.53$12.3KHUN
7$16,802$26.30$35,936$6,040.61$19.1KHUN
8$17,998$19.23$47,841$9,388.67$29.8KHUN
9$19,272$14.05$66,293$15,103.63$47.0KHUN
10$20,631$10.26$96,225$25,291.10$75.6KHUN

BAX vs HUN: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

HUNMaterials

Huntsman Corporation manufactures and sells differentiated organic chemical products worldwide. The company operates through four segments: Polyurethanes, Performance Products, Advanced Materials, and Textile Effects. The Polyurethanes segment offers polyurethane chemicals, including methyl diphenyl diisocyanate, polyols, thermoplastic polyurethane, propylene oxide, and methyl tertiary-butyl ether products. The Performance Products segment manufactures amines and maleic anhydrides, including ethylene oxide, propylene oxide, glycols, ethylene dichloride, caustic soda, ammonia, hydrogen, methylamines, and acrylonitrile. The Advanced Materials segment offers epoxy, acrylic, polyurethane, and acrylonitrile-butadiene-based polymer formulations; high performance thermoset resins, curing agents and toughening agents, and carbon nanotubes additives; and base liquid and solid resins. The Textile Effects segment provides textile chemicals and dyes. The company's products are used in a range of applications, including adhesives, aerospace, automotive, construction products, durable and non-durable consumer products, electronics, insulation, medical, packaging, coatings and construction, power generation, refining, synthetic fiber, textile chemicals, and dye industries. Huntsman Corporation was founded in 1970 and is headquartered in The Woodlands, Texas.

Full HUN Calculator →
📬

Get this BAX vs HUN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.